

Title (en)  
METHODS AND COMPOSITIONS FOR TREATING AND MONITORING TREATMENT OF IL-13-ASSOCIATED DISORDERS

Title (de)  
VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG UND ÜBERWACHUNG DER BEHANDLUNG VON MIT IL 13 ASSOZIIERTEN ERKRANKUNGEN

Title (fr)  
METHODES ET COMPOSITIONS POUR LE TRAITEMENT ET LE CONTROLE D'UN TRAITEMENT DE TROUBLES ASSOCIES A IL-13

Publication  
**EP 2089057 A2 20090819 (EN)**

Application  
**EP 07867722 A 20071211**

Priority  
• US 2007025418 W 20071211  
• US 87433306 P 20061211  
• US 92593207 P 20070423

Abstract (en)  
[origin: WO2008073463A2] Methods and compositions for treating and/or monitoring treatment of IL-13-associated disorders or conditions are disclosed.

IPC 8 full level  
**A61K 39/395** (2006.01); **A61K 38/17** (2006.01); **A61P 37/06** (2006.01); **C07K 14/715** (2006.01); **C07K 16/24** (2006.01)

CPC (source: EP)  
**A61K 39/39533** (2013.01); **A61P 1/04** (2017.12); **A61P 1/16** (2017.12); **A61P 7/00** (2017.12); **A61P 11/00** (2017.12); **A61P 11/02** (2017.12); **A61P 17/00** (2017.12); **A61P 17/04** (2017.12); **A61P 29/00** (2017.12); **A61P 31/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 37/00** (2017.12); **A61P 37/06** (2017.12); **A61P 43/00** (2017.12); **C07K 16/247** (2013.01); **G01N 33/6869** (2013.01); **A61K 2039/505** (2013.01); **C07K 2317/34** (2013.01)

C-Set (source: EP)  
**A61K 39/39533 + A61K 2300/00**

Citation (search report)  
See references of WO 2008073463A2

Citation (examination)  
• CETRE C ET AL: "Interleukin-13 and IgE production in rat experimental schistosomiasis", EUROPEAN CYTOKINE NETWORK, JOHN LIBBEY EUROTTEXT LTD, FR, vol. 11, no. 2, 1 June 2000 (2000-06-01), pages 241 - 249, XP008090844, ISSN: 1148-5493  
• TAUBE CHRISTIAN ET AL: "The role of IL-13 in established allergic airway disease.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 DEC 2002 LNKD- PUBMED:12444158, vol. 169, no. 11, 1 December 2002 (2002-12-01), pages 6482 - 6489, ISSN: 0022-1767  
• HART T K ET AL: "Preclinical efficacy and safety of pascolizumab (SB 240683): A humanized anti-interleukin-4 antibody with therapeutic potential in asthma", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 130, no. 1, 1 October 2002 (2002-10-01), pages 93 - 100, XP002434532, ISSN: 0009-9104, DOI: DOI:10.1046/J.1365-2249.2002.01973.X  
• YANG GAOYUN ET AL: "Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS APR 2005 LNKD- PUBMED:15644434, vol. 313, no. 1, April 2005 (2005-04-01), pages 8 - 15, XP002644930, ISSN: 0022-3565, DOI: doi:10.1124/jpet.104.076133  
• PERKINS ET AL: "IL-4 induces IL-13-independent allergic airway inflammation", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY, INC, US, vol. 118, no. 2, 1 August 2006 (2006-08-01), pages 410 - 419, XP005587359, ISSN: 0091-6749, DOI: DOI:10.1016/J.JACI.2006.06.004

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**WO 2008073463 A2 20080619**; **WO 2008073463 A3 20081002**; BR PI0720280 A2 20140128; CA 2672215 A1 20080619; EP 2089057 A2 20090819; JP 2010512402 A 20100422; MX 2009005725 A 20090824; RU 2009120202 A 20110120

DOCDB simple family (application)  
**US 2007025418 W 20071211**; BR PI0720280 A 20071211; CA 2672215 A 20071211; EP 07867722 A 20071211; JP 2009541364 A 20071211; MX 2009005725 A 20071211; RU 2009120202 A 20071211